Get the content you want anytime you want.
2019 Annual MAD-ID Meeting

Select coverage from 2019 Annual MAD-ID Meeting is included below:

Next Steps for Research on Gram-Negative Skin Infections
Glenn Tillotson, PhD, discusses possible avenues for future research on gram-negative skin infections and inappropriate empiric therapy.
Decreasing Patient Exposure to Vancomycin
Matthew Girgis, PharmD, PGY-2, discusses why it's advantageous to decrease patient exposure to vancomycin.
Why ID? Experts Share The 'Why' That Drove Them to Pursue Infectious Disease Careers
We asked providers in the field why they pursued a career in infectious disease.
Inappropriate Empiric Therapy as a Driver of Poor Outcomes
Glenn Tillotson, PhD, explains how inappropriate empiric therapy can drive poor outcomes.
Rapid Diagnostics for Gram-Negative Bloodstream Infections
Kimberly Claeys, PharmD, discusses the need for more data on rapid diagnostics for gram-negative bloodstream infections.
Time to Clinical Response as a Valuable Metric
Thomas Lodise, PharmD, PhD, discusses why "time to clinical response" is a valuable metric to use in clinical studies.
Alison Lew, PharmD: Vancomycin Prophylaxis for CDI Recurrence
At MAD-ID 2019, Alison Lew, PharmD, spoke about her research on oral vancomycin prophylaxis to reduce CDI recurrence. 
Renee Ackley, PharmD, BCPS: Comparing Agents for Treating CRE
Renee Ackley, PharmD, BCPS, discusses her research ceftazidime/avibactam and meropenem/vaborbactam for treatment of CRE infections.
Is there a cure? How long until we find it? And will it work for the majority of people living with HIV?